- US-listed companies
- IMMUNIC, INC.
- Income statement
IMMUNIC, INC. (IMUX) Income statement
Market cap
$1.3B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Research & development | 39 | 40 | 30 | 39 | 25 | 23 | 39 | 61 | 71 | 83 | 80 | 82 |
| Operating expenses | 50 | 52 | 41 | 53 | 42 | 37 | 49 | 92 | 119 | 99 | 98 | 103 |
| Operating income | -50 | -52 | -41 | -53 | -42 | -37 | -49 | -92 | -119 | -99 | -98 | -103 |
| Net income | -48 | -52 | -41 | -52 | -41 | -35 | -44 | -93 | -120 | -94 | -101 | -97 |
| Earnings per share | - | - | - | - | - | - | - | -3.93 | -3.78 | -2.11 | -1 | -0.62 |
| Diluted EPS | - | - | - | - | - | - | - | -3.93 | -3.78 | -2.11 | -1 | -0.62 |
| EBITDA |